How to use the speech recognition tool?

NCT03584165

SOLSTICE

A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Type: Observational



Status of the trial: Active, Recruiting

Orphan Drug Recognition: Yes

Inclusion

  • Opening Date: 2017-01-01
  • Closing Date: 2027-03-27

Criteria

Inclusion: Subjects are willing and able to give informed consent for participation in the study, and have received a sub-retinal injection of AAV2-REP1 for CHM in an antecedent study.

Exclusion: There are no exclusion criteria for this study.

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: